HEAD AND NECK SQUAMOUS CELL CARCINOMA
Clinical trials for HEAD AND NECK SQUAMOUS CELL CARCINOMA explained in plain language.
Never miss a new study
Get alerted when new HEAD AND NECK SQUAMOUS CELL CARCINOMA trials appear
Sign up with your email to follow new studies for HEAD AND NECK SQUAMOUS CELL CARCINOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New combo shows promise for head and neck cancer patients unable to take standard chemo
Disease control CompletedThis study tested two different drugs—durvalumab or cetuximab—given together with radiation therapy for people with advanced head and neck cancer who cannot take the standard chemotherapy drug cisplatin. The goal was to see which combination works better and is safer. A total of …
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE2, PHASE3 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated May 17, 2026 02:15 UTC
-
Engineered immune cells take on HPV cancers in early trial
Disease control CompletedThis early-stage trial tested a new treatment for people with HPV16-positive head and neck or cervical cancer that had spread or come back. The therapy uses a patient's own immune cells, specially trained to recognize and attack HPV-infected cancer cells. Some of these cells were…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE1 • Sponsor: Xinqiao Hospital of Chongqing • Aim: Disease control
Last updated May 17, 2026 02:14 UTC
-
Supercharged immune cells take on Hard-to-Treat head and neck cancer
Disease control CompletedThis trial tested a new treatment for people with a type of head and neck cancer linked to the Epstein-Barr virus (EBV). The treatment uses specially engineered immune cells (TCR-T cells) that can recognize and attack cancer cells, plus they release a substance to block a common …
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: Xinqiao Hospital of Chongqing • Aim: Disease control
Last updated May 17, 2026 02:06 UTC
-
Experimental combo shows promise against tough cancers
Disease control CompletedThis study tested a combination of two drugs—sEphB4-HSA and pembrolizumab—in 42 people with advanced non-small cell lung cancer or head & neck cancer that had spread or come back. The goal was to see if the combo could shrink tumors better than standard treatments. Participants h…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE2 • Sponsor: University of Southern California • Aim: Disease control
Last updated May 17, 2026 02:06 UTC
-
Can a nitric oxide blocker make immunotherapy work better?
Disease control CompletedThis early-phase trial tested whether adding L-NMMA to the immunotherapy drug pembrolizumab is safe for people with several types of advanced cancer. The idea is that L-NMMA may remove a brake on the immune system, helping pembrolizumab work better. Only 12 adults took part, and …
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE1 • Sponsor: The Methodist Hospital Research Institute • Aim: Disease control
Last updated May 17, 2026 02:05 UTC
-
Can quitting smoking help fight cancer? new study tests a support program
Disease control CompletedThis study tested a special smoking cessation program for people with head and neck or lung cancer. The program included counseling, medication, and nicotine replacement to help patients cut down or quit smoking. Researchers wanted to see if reducing smoking could also change the…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: NA • Sponsor: Thomas Jefferson University • Aim: Disease control
Last updated May 17, 2026 02:04 UTC
-
New cancer drug shows promise in Head-to-Head trial against standard therapy
Disease control CompletedThis study tested a new drug called RPH-002 against the standard drug Erbitux in 118 people with advanced head and neck cancer that cannot be removed by surgery. The goal was to see how the body processes each drug and to compare their safety when used with chemotherapy. The stud…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE1 • Sponsor: R-Pharm • Aim: Disease control
Last updated May 17, 2026 02:04 UTC
-
Double-Drug attack shows promise for tough head and neck cancers
Disease control CompletedThis study tested whether combining two approved cancer drugs, cetuximab and nivolumab, could help people with advanced head and neck cancer that has returned or spread. About 95 adults with this type of cancer took part. The goal was to see if the combination was safe and could …
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: H. Lee Moffitt Cancer Center and Research Institute • Aim: Disease control
Last updated May 17, 2026 02:03 UTC
-
New drug combo shows promise for tough head and neck cancers
Disease control CompletedThis study tested whether adding tadalafil (a drug for erectile dysfunction) to pembrolizumab (an immunotherapy) could help people with advanced head and neck cancer that has spread or come back. Seven adults with this cancer took part. The goal was to see if the combination was …
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE2 • Sponsor: University of California, San Diego • Aim: Disease control
Last updated May 17, 2026 02:03 UTC
-
Immunotherapy combo shows promise against tough head and neck cancers
Disease control CompletedThis study tested a new treatment approach for people with advanced head and neck cancer that cannot be removed by surgery. The treatment combined the immunotherapy drug camrelizumab with chemotherapy and radiation, followed by camrelizumab alone. The goal was to see if this comb…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE2 • Sponsor: Chongqing University Cancer Hospital • Aim: Disease control
Last updated May 17, 2026 02:00 UTC
-
Yeast vaccine trains immune system to fight returning cancer
Disease control CompletedThis early-phase study tested a custom-made yeast vaccine designed to teach the immune system to recognize and attack leftover cancer cells. Five adults with different solid tumors (like colorectal, breast, or lung cancer) who had already completed curative treatment received the…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE1 • Sponsor: NantBioScience, Inc. • Aim: Disease control
Last updated May 15, 2026 11:57 UTC
-
New pill for advanced cancers enters first human tests
Disease control CompletedThis early-phase study tested an experimental oral drug called JAB-3312 in 40 adults with advanced solid tumors (such as lung, colon, or breast cancer) that had stopped responding to standard treatments. The main goal was to find a safe dose and understand side effects. Participa…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE1 • Sponsor: Jacobio Pharmaceuticals Co., Ltd. • Aim: Disease control
Last updated May 15, 2026 11:57 UTC
-
New drug combo shows promise against tough head and neck cancer
Disease control CompletedThis study tested a combination of two drugs, ramucirumab and pembrolizumab, in 43 people with head and neck cancer that had spread or come back. The goal was to see if the combination was safe and effective at shrinking tumors. The trial had two parts: first finding a safe dose,…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE1, PHASE2 • Sponsor: Washington University School of Medicine • Aim: Disease control
Last updated May 15, 2026 11:56 UTC
-
AI shrinks radiation target, spares healthy tissue in head and neck cancer
Disease control CompletedThis study tested a new way to give radiation for head and neck cancer. Instead of treating the whole neck, doctors used artificial intelligence to focus radiation only on the cancer spots. 67 patients took part to see if this approach could control the disease while causing fewe…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE2 • Sponsor: University of Texas Southwestern Medical Center • Aim: Disease control
Last updated May 15, 2026 11:54 UTC
-
New drug combo shows promise against tough head and neck cancer
Disease control CompletedThis study tested whether adding lenvatinib to pembrolizumab helps people with advanced head and neck cancer that has come back or spread. About 511 adults with a specific type of head and neck cancer took part. The goal was to see if the combination shrinks tumors, delays cancer…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated May 14, 2026 12:06 UTC
-
New combo shows promise against three tough cancers
Disease control CompletedThis study tested a new drug combination (IO102-IO103 plus pembrolizumab) as a first treatment for people with advanced lung, head/neck, or bladder cancer that had spread. A total of 63 patients took part. The goal was to see if the combo could shrink tumors and delay cancer grow…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE2 • Sponsor: IO Biotech • Aim: Disease control
Last updated May 14, 2026 12:03 UTC
-
New drug combo shows promise for Tough-to-Treat head and neck cancer
Disease control CompletedThis study tested whether adding lenvatinib to pembrolizumab helps people with advanced head and neck cancer that has come back or spread. 112 adults with a specific marker (PD-L1 positive) received either the drug combo or pembrolizumab alone. The goal was to see if the combinat…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated May 11, 2026 20:49 UTC
-
New drug combo shows promise for Tough-to-Treat head and neck cancer
Disease control CompletedThis study tested a combination of two drugs, pembrolizumab and cetuximab, in 78 people with advanced head and neck cancer that had come back or spread. The goal was to see if the combo could shrink tumors or slow the disease. Participants were grouped based on whether they had r…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: PHASE2 • Sponsor: University of California, San Diego • Aim: Disease control
Last updated Apr 26, 2026 20:00 UTC
-
Blood test may replace needle biopsy for some cancers
Diagnosis CompletedThis study tested whether a new blood test (liquid biopsy) can accurately find cancer biomarkers in patients with head and neck, lung, or skin cancer. 135 adults with advanced cancer provided blood and tumor tissue samples. The goal was to see if the blood test works as well as t…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA
Sponsor: Pharmassist Ltd • Aim: Diagnosis
Last updated May 11, 2026 20:39 UTC
-
Personalized blood test may predict head and neck cancer relapse
Knowledge-focused CompletedThis study looked at whether a custom blood test can find tiny bits of tumor DNA in 40 patients with advanced head and neck cancer. Researchers checked blood before surgery, after surgery, and for 18 months afterward. The goal was to see if this test could help predict if the can…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: NA • Sponsor: Centre Henri Becquerel • Aim: Knowledge-focused
Last updated May 17, 2026 02:03 UTC
-
Tumor biobank holds key to personalized head and neck cancer care
Knowledge-focused CompletedThis study collected tumor samples from 419 adults with head and neck cancer to create a biobank for future research. The goal is to use genetic information from these samples to better predict how each patient will respond to treatment. No direct treatment was given; the focus i…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA
Sponsor: Maastricht Radiation Oncology • Aim: Knowledge-focused
Last updated May 17, 2026 02:02 UTC
-
New MRI technique may spot cancer recurrence early
Knowledge-focused CompletedThis study looked at whether a type of MRI called diffusion-weighted MRI can predict if head and neck cancer will return after chemoradiotherapy. Researchers enrolled 59 patients and used the scan to measure water movement in tumors. The goal was to see if early changes could sig…
Matched conditions: HEAD AND NECK SQUAMOUS CELL CARCINOMA
Phase: NA • Sponsor: CHU de Reims • Aim: Knowledge-focused
Last updated May 17, 2026 02:01 UTC